---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-104602"
form_type: "8-K"
ticker: "MBX"
cik: "0001776111"
company_name: "MBX Biosciences, Inc."
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T18:01:14.613224+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# MBX Biosciences Q2 net loss $19.4M; cash $224.9M; canvuparatide Phase 2 data on track for Q3 2025

## Summary
- Net loss $19.4M for Q2 2025 vs $15.9M in Q2 2024; R&D expenses increased to $17.7M.
- Cash, equivalents and marketable securities $224.9M as of June 30, 2025; expected to fund operations into mid-2027.
- Phase 2 Avail trial of canvuparatide in hypoparathyroidism topline results expected in Q3 2025.
- Phase 2a trial of imapextide (post-bariatric hypoglycemia) and Phase 1 trial of MBX 4291 (obesity) to initiate in Q3 2025.
- Appointed Dr. Andreas Moraitis as SVP of Clinical Development in June 2025.

## SEC filing metadata
- accession: 0000950170-25-104602
- form_type: 8-K
- ticker: MBX
- cik: 0001776111
- company_name: MBX Biosciences, Inc.
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1776111/000095017025104602/0000950170-25-104602-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1776111/000095017025104602/mbx-20250807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-104602
- JSON: https://secwatch.observer/filing/0000950170-25-104602.json
- Plain text: https://secwatch.observer/filing/0000950170-25-104602.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.